Last updated:
Author(s):
Linda Garvert, Kevin Kirchner, Hans J Grabe, Sandra Van der Auwera
Publish date:
14 August 2022
Journal:
Progress in Neuro-Psychopharmacology and Biological Psychiatry
PubMed ID:
35977647

Abstract

Recent genome-wide association studies (GWAS) have identified numerous single nucleotide polymorphisms affecting depressive disorders. GWAS results support the heterogeneity of depression as a disorder affected by a large number of genetic variants with mainly small effect sizes. However, not much is known about the interplay of different genetic risk factors. Moreover, recent studies are questioning the role of common candidate genes in the development of depressive disorders. One such candidate variant is the serotonin-transporter-promoter-polymorphism 5-HTTLPR in the SLC6A4 gene. We hypothesize that 5-HTTLPR exerts its effect on depressive disorders in interaction with other genetic variants. In the present study we test this hypothesis using a genome-wide gene-gene interaction approach on a large sample from the UK Biobank (N = 127,558). We identified a region in the DPF1 gene that displayed a genome-wide significant (p = 3.31 × 10-7) interaction effect with the biallelic version of 5-HTTLPR on lifetime depression. DPF1 has not previously been described as risk factor for depressive disorders but is exclusively expressed in the brain as a major regulator of neuronal development and neuroplasticity. This study stresses the need for further analyses that take into consideration the fact that genetic variants do operate in biological networks.

Related projects

Studies have shown that persons with metabolic alterations are more likely to develop depressive symptoms or even a depressive disorder. At the same time the…

Institution:
University Medicine Greifswald, Germany

All projects